Genmab — Juli 2025

[E_L]

Small new trial - A Study of Epcoritamab and Ibrutinib in People With Central Nervous System Lymphoma (CNSL) https://clinicaltrials.gov/study/NCT07082868

[w]

Uden jinxe for meget, så har vi vel brudt den lange nedtrend for første gang i 2.5år

[ProinvestorNEWS]

Sanofi's Sarclisa Combination Gets EU Approval For Treating Newly Diagnosed Multiple Myeloma https://proinvestor.com/investornyt/1342936/sanofis-sarclisa-combination-gets-eu-approval-for-treating-newly-diagnosed-multiple-myeloma

[BSinvest]

w... Aktien stadig er i en nedadgående trend. Afvent et brud over 1.650 DKK for at bekræfte en potentiel vending.

[BSinvest]

Vendingen skal helst ske med stigende RSI og øget handelsvolumen for at bekræfte at trenden for alvor er stigende.

[E_L]

A hexamerization-enhanced, Fc-silenced agonistic CD27 antibody amplifies T-cell effector functions as single agent and in combination with PD-1 blockade https://www.nature.com/articles/s41598-025-11990-z

[gentogen]

The study of this was terminated prior to the start of the Dose Expansion Phase.NCT05435339. Many positive things in the article, but I kind of lack a coclusion about the development as ended or not?

[E_L]

They discontinued the clinical development.

[E_L]

this is what it said last august24: Following a strategic evaluation of GEN1053 within the context of
Genmab’s and BioNTech’s portfolios, a decision was made to discontinue the Phase 1/2 clinical trial
(NCT05435339) of GEN1053 in solid tumors. Preclinical activities remain ongoing.

[E_L]

whether those preclinical activities aim to return with something on Hexabody-CD27 I don't know (but i doubt it). Maybe it is to get more info on the Hexabody technology

[E_L]

But both Özlem Türeci & Uğur Şahin from biontech co-authored it, so they must have deemed it of interest

[gentogen]

Thanks a lot for the extra info.

[Helge_LarsenPI-redaktør]

Godmorgen

[Stroka]

God morgen

[ProinvestorNEWS]

Genmab Transcript Special Call: Ser Rina-S i markedet i 2027 med peak-salg på 2 mia. USD https://proinvestor.com/investornyt/1343403/genmab-transcript-special-call-ser-rina-s-i-markedet-i-2027-med-peak-salg-pa-2-mia-usd

[Bulder]

Tak til ØU for fremskaffelse og udarbejdelse af fortrinligt materiale.

[E_L]

ESMO 2025 Industry Satellite Symposium

Genmab - Advancing Antibody-Drug Conjugates Into the Future of Gynecologic Malignancies https://cslide.ctimeetingtech.com/esmo2025/attendee/confcal/session/calendar?q=genmab

[E_L]

ESMO 2025 1121P - Rinatabart sesutecan (Rina-S) for patients with advanced or recurrent endometrial cancer (a/r EC): Update from dose expansion cohort B2 of RAINFOL-01

[E_L]

ESMO 2025 1166P - Tisotumab Vedotin Plus Carboplatin or Pembrolizumab in Recurrent or Metastatic Cervical Cancer: 5-Year Results From the innovaTV 205/GOG-3024/ENGOT-cx8 Study

[ProinvestorNEWS]

Teknisk: Genmab bryder op gennem 200 MA, mere i vente mandag https://proinvestor.com/investornyt/1343407/teknisk-genmab-bryder-op-gennem-200-ma-mere-i-vente-mandag